• 1
    Sleight P. Current options in the management of coronary artery disease. Am J Cardiol 2003;92:48.
  • 2
    Agema WR, Monraats PS, Zwinderman AH, De Winter RJ, Tio RA, Doevendans PA et al. Current PTCA practice and clinical outcomes in the Netherlands: the real world in the pre-drugeluting stent era. Eur Heart J 2004;25:116370.
  • 3
    Hasdai D, Behar S, Boyko V, Danchin N, Bassand JP, Battler A. Cardiac biomarkers and acute coronary syndromes – the Euro Heart Survey of Acute Coronary Syndromes Experience. Eur Heart J 2003;24:118994.
  • 4
    Wiest FC, Bryson CL, Burman M, McDonell MB, Henikoff JG, Fihn SD. Suboptimal pharmacotherapeutic management of chronic stable angina in the primary care setting. Am J Med 2004;117:23441.
  • 5
    Denhardt DT, Noda M, O’Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001;107:105561.
  • 6
    Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontin-a molecule for all seasons. QJM 2002;95:313.
  • 7
    Okamoto H. Osteopontin and the cardiovascular system. Mol Cell Biochem 2007;300:17.
  • 8
    Fitzpatrick LA, Severson A, Edwards WD, Ingram RT. Diffuse calcification in human coronary arteries: association of osteopontin with atherosclerosis. J Clin Invest 1994;94:1597604.
  • 9
    Ohmori R, Momiyama Y, Taniguchi H, Takahashi R, Kusuhara M, Nakamura H et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003;170:3337.
  • 10
    Kato R, Momiyama Y, Ohmori R, Tanaka N, Taniguchi H, Arakawa K et al. High plasma levels of osteopontin in patients with restenosis after percutaneous coronary intervention. Arterioscler Thromb Vasc Biol 2006;26:12.
  • 11
    Minoretti P, Falcone C, Calcagnino M, Emanuele E, Buzzi MP, Coen E et al. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J 2006;27:8027.
  • 12
    Rosenberg M, Zugck C, Nelles M, Juenger C, Frank D, Remppis A et al. Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail 2008;1:439.
  • 13
    Riedl M, Vila G, Maier C, Handisurya A, Shakeri-Manesch S, Prager G et al. Plasma osteopontin increases after bariatric surgery and correlates with markers of bone turnover but not with insulin resistance. J Clin Endocrinol Metab 2008;93:230712.
  • 14
    Staal A, Van Wijnen AJ, Desai RK, Pols HA, Birkenhäger JC, Deluca HF et al. Antagonistic effects of transforming growth factor-beta on vitamin D3 enhancement of osteocalcin and osteopontin transcription: reduced interactions of vitamin D receptor/retinoid X receptor complexes with vitamin E response elements. Endocrinology 1996;137:200111.
  • 15
    Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007;27:23029.
  • 16
    Xie Z, Singh M, Singh K. ERK1/2 and JNKs, but not p38 kinase, are involved in reactive oxygen species-mediated induction of osteopontin gene expression by angiotensin II and interleukin-1beta in adult rat cardiac fibroblasts. J Cell Physiol 2004;198:399407.
  • 17
    Ashizawa N, Graf K, Do YS, Nunohiro T, Giachelli CM, Meehan WP et al. Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. Clin Invest 1996;98:221827.
  • 18
    Georgiadou P, Iliodromitis EK, Varounis C, Mavroidis M, Kolokathis F, Andreadou I et al. Relationship between plasma osteopontin and oxidative stress in patients with coronary artery disease. Expert Opin Ther Targets 2008;12:91720.
  • 19
    Georgiadou P, Iliodromitis EK, Kolokathis F, Mavroidis M, Andreadou I, Demopoulou M et al. Plasma levels of osteopontin before and 24 hours after percutaneous coronary intervention. Expert Opin Ther Targets 2008;12:147780.
  • 20
    Singh K, Sirokman G, Communal C, Robinson KG, Conrad CH, Brooks WW et al. Myocaridal osteopontin expression coincides with the development of heart failure. Hypertension 1999;33:66370.
  • 21
    Graf K, Do YS, Ashizawa N, Meehan WP, Giachelli CM, Marboe CC et al. Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation 1997;96:306371.
  • 22
    Mavroidis M, Capetanaki Y. Extensive induction of important mediators of fibrosis and dystrophic calcification in desmin-deficient cardiomyopathy. Am J Pathol 2002;160:94352.
  • 23
    Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004;24:116170.
  • 24
    Detrano R, Hsiai T, Wang S, Puentes G, Fallavollita J, Shields P et al. Prognostic value of coronary calcification and angiographic stenoses in patients undergoing coronary angiography. J Am Coll Cardiol 1996;27:28590.
  • 25
    Pass HI, Lott D, Leonardo F, Harbut M, Liu Z, Tang N et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005;353:156473.
  • 26
    Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002;287:16719.
  • 27
    Schnabel R, Rupprecht HJ, Lackner KJ, Lubos E, Bickel C, Meyer J et al. AtheroGene Investigators. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur Heart J 2005;26:2419.
  • 28
    Vordermark D, Said HM, Katzer A, Kuhnt T, Hänsgen G, Dunst J et al. Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer 2006;6:207.